Want to see KNSA full AI Analyst Report?
Kiniksa Pharmaceuticals (KNSA) Income Statement
Kiniksa Pharmaceuticals Income Statement
Last quarter (Q3 2026), Kiniksa Pharmaceuticals's total revenue was $285.97M, an increase of 58.12% from the same quarter last year. In Q3, Kiniksa Pharmaceuticals's net income was $47.34M. See Kiniksa Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 677.56M | $ 423.24M | $ 270.26M | $ 220.18M | $ 38.54M | |
| $ 370.15M | $ 362.33M | $ 213.74M | $ 197.28M | $ 29.44M | |
| $ 292.93M | $ 407.94M | $ 238.93M | $ 187.51M | $ 186.08M | |
| Depreciation and Amortization | $ 1.55M | $ 1.70M | $ 2.34M | $ 2.40M | $ 2.35M |
| $ 90.42M | $ -34.46M | $ -14.31M | $ 13.43M | $ -154.18M | |
| $ 77.22M | $ -45.62M | $ -25.20M | $ 9.77M | $ -156.64M | |
| $ 11.65M | $ 9.46M | $ 8.54M | $ 1.25M | $ 97.00K | |
| $ 88.87M | $ -36.15M | $ -16.65M | $ 11.03M | $ -156.54M | |
| $ 59.01M | $ -43.19M | $ 14.08M | $ 183.36M | $ -157.92M | |
| Per Share Metrics | |||||
| Basic EPS | $ 0.80 | $ -0.60 | $ 0.20 | $ 2.64 | $ -2.30 |
| Diluted EPS | $ 0.75 | $ -0.60 | $ 0.20 | $ 2.60 | $ -2.30 |
| Weighted Average Shares Outstanding | 74.20M | 71.42M | 70.06M | 69.38M | 68.58M |
| Weighted Average Shares Outstanding (Diluted) | 78.98M | 71.42M | 71.92M | 70.42M | 68.58M |
Currency in USD